Peptides Secreted by the Pituitary Gland

The pituitary gland secretes various hormones that regulate different bodily functions. The posterior lobe of the pituitary gland secretes two peptides, oxytocin and antidiuretic hormone (ADH). Oxytocin, which is produced in the hypothalamus, stimulates uterine contractions during labor and is involved in the release of milk from the lactating breast. ADH, also known as vasopressin, is also produced in the hypothalamus and regulates water balance in the body.

On the other hand, the anterior lobe of the pituitary gland secretes six peptide hormones. These hormones include adrenocorticotrophic hormone (ACTH), prolactin, thyroid-stimulating hormone (TSH), growth hormone (GH), follicle-stimulating hormone (FSH), and luteinizing hormone (LH). ACTH stimulates the adrenal gland to produce cortisol, which helps the body respond to stress. Prolactin stimulates milk production in the mammary glands. TSH stimulates the thyroid gland to produce thyroid hormones, which regulate metabolism. GH promotes growth and development in children and helps maintain muscle and bone mass in adults. FSH and LH regulate the reproductive system, with FSH stimulating the growth of ovarian follicles in females and sperm production in males, while LH triggers ovulation in females and testosterone production in males.

Referral for Suspected Androgen-Secreting Tumour in a Patient with Hirsutism

This patient presents with sudden-onset hair growth and a raised testosterone level, which raises suspicion for an androgen-secreting tumour. An urgent referral for further investigation is necessary to rule out malignancy. While polycystic ovary syndrome can also cause hirsutism, the patient’s testosterone level warrants exclusion of a tumour. Topical eflornithine may provide symptomatic relief, but it is not a substitute for further investigation. Routine referral to endocrinology is not appropriate in this case, as it may delay diagnosis and treatment of a potential malignancy.

Management of Hypercholesterolemia in a Patient with Suspected Hypothyroidism

To manage hypercholesterolemia in a patient with suspected hypothyroidism, it is important to confirm the diagnosis of hypothyroidism first. Blood tests for thyroid function, specifically thyroid-stimulating hormone and free T4, should be conducted. If hypothyroidism is confirmed, it should be treated accordingly.

Statin therapy, such as atorvastatin, is the first-line pharmacological agent for managing hypercholesterolemia. However, in this case, potential hypothyroidism needs to be treated first before starting statin therapy. If high cholesterol levels persist after treating hypothyroidism, a statin therapy can be started, and fibrate therapy can be added if necessary.

While dietary and lifestyle advice is important, it is unlikely to address the underlying problems in this case. Therefore, it is crucial to confirm and treat hypothyroidism before managing hypercholesterolemia.

Diagnosis and Management of Primary Hypothyroidism

The patient’s test results indicate a case of primary hypothyroidism, characterized by low levels of thyroxine (T4) and elevated thyroid-stimulating hormone (TSH). The most likely cause of this condition is Hashimoto’s thyroiditis, which is often accompanied by the presence of thyroid peroxidase antibodies. While the patient has a goitre, it appears to be smooth and non-threatening, so a thyroid ultrasound is not necessary. Additionally, a radio-iodine uptake scan is unlikely to show significant uptake and is therefore not recommended. Positive TSH receptor antibodies are typically associated with Graves’ disease, which is not the likely diagnosis in this case. For further information on Hashimoto’s thyroiditis, patients can refer to Patient.info.

BMI is a calculation of weight over height squared and is used to determine if someone is underweight, normal weight, overweight, or obese. A BMI above 30 indicates obesity and is associated with increased risks for various health issues and surgical complications.

The Thyroid Hormone Axis

The thyroid hormone axis is a complex system that involves the hypothalamus, pituitary gland, and thyroid gland. The hypothalamus produces a hormone called thyrotropin-releasing hormone (TRH), which stimulates the anterior pituitary gland to release thyroid-stimulating hormone (TSH). TSH then stimulates the thyroid gland to produce and release the thyroid hormones thyroxine (T4) and tri-iodothyronine (T3).

Both T4 and T3 are primarily bound to proteins in the bloodstream, but it is the free, unbound hormones that are biologically active. The secretion of TSH is inhibited by the presence of thyroid hormones in the bloodstream. This negative feedback loop helps to regulate the levels of thyroid hormones in the body.

In summary, the thyroid hormone axis is a tightly regulated system that involves multiple hormones and glands working together to maintain proper levels of thyroid hormones in the body.

Management of Primary Hyperparathyroidism: Indications for Surgery and Treatment Options

Primary hyperparathyroidism is a condition characterized by persistent hypercalcemia with an inappropriately elevated or normal parathyroid hormone (PTH). Patients with this condition may also have hypercalciuria, which can lead to renal stones and nephrocalcinosis. Parathyroidectomy is the recommended treatment for primary hyperparathyroidism, with success rates of about 97%.

Indications for parathyroidectomy include symptomatic disease, age under 50 years, adjusted serum calcium concentration that is 0.25 mmol/l or more above the upper end of the reference range, estimated glomerular filtration rate (eGFR) less than 60 ml/min/1.73 m2, renal stones or presence of nephrocalcinosis on ultrasound or CT, and presence of osteoporosis or osteoporotic fracture.

Patients with calcium >3.4 mmol/l or who are significantly symptomatic or have an acute kidney injury and dehydration should be admitted for urgent treatment and assessment. However, asymptomatic patients with normal renal function and likely longstanding hypercalcemia may not require hospitalization.

For patients who are not candidates for surgery or decline it, other treatment options include bisphosphonate therapy, cinacalcet, and vitamin D replacement. Bisphosphonate therapy can improve bone mineral density but will not prevent further renal stones. Cinacalcet is an allosteric modulator of the calcium-sensing receptor that can be used in patients who meet hypercalcemia criteria for parathyroidectomy but cannot undergo surgery. However, it can cause mild-to-moderate adverse events such as nausea, vomiting, arthralgia, diarrhea, myalgia, and paraesthesia. Vitamin D replacement should be considered if vitamin D levels are low, but careful monitoring is required to avoid masking hypercalcemia and increasing the risk of parathyroid tumorigenesis.

In summary, the management of primary hyperparathyroidism involves identifying indications for parathyroidectomy and considering alternative treatment options for patients who are not candidates for surgery or decline it. Close monitoring and follow-up are essential to ensure optimal outcomes.

Causes of Hyponatraemia: Differential Diagnosis

Hyponatraemia is a common electrolyte disturbance that can be caused by a variety of conditions. In this case, the patient’s acute confusional state is likely due to significant hyponatraemia. The low serum urea level and osmolality suggest dilutional hyponatraemia, but the raised urine osmolality indicates continued secretion of antidiuretic hormone (ADH), known as syndrome of inappropriate ADH secretion (SIADH).

SIADH can be associated with malignancy (such as small cell lung cancer), central nervous system disorders, drugs, and major surgery. In this patient’s case, the unifying diagnosis is small cell lung cancer causing SIADH. Digital clubbing also points towards a diagnosis of lung cancer.

Other conditions that can cause hyponatraemia include nephrotic syndrome, Addison’s disease, cystic fibrosis, and excessive diuretic therapy. However, these conditions have different biochemical profiles and clinical features.

Therefore, a thorough differential diagnosis is necessary to determine the underlying cause of hyponatraemia and guide appropriate management.

Insulin Types and Mixtures

Insulin is a hormone that regulates blood sugar levels in the body. Premix or mixed insulin is a combination of short and long-acting insulin. It is identified by a number that represents the percentage of rapid-acting insulin it contains. For instance, Novomix 30 has 30% rapid-acting insulin and 70% long-acting insulin. Mixed insulin is usually taken twice daily and must be administered with meals as it contains rapid-acting insulin.

Insulin detemir, also known as Levemir, is a long-acting analogue that lasts for about 12-20 hours and is usually given twice a day. Insulin glargine, also known as Lantus, is another long-acting analogue that lasts for about 20-24 hours and is usually given once a day. Novorapid is a fast-acting insulin that is often used to cover the increase in blood glucose levels following a meal. Patients taking Novorapid will usually require treatment with a long-acting insulin.

Exenatide is an injectable therapy for type 2 diabetes that is based on the hormone glucagon-like peptide 1 (GLP-1) and is not insulin. It is important to note that lipohypertrophy can occur in all insulin treatments. This refers to the accumulation of fatty deposits at injection sites, which can affect the rate of insulin absorption and, in turn, affect the patient’s glycaemic control. Therefore, it is crucial to rotate injection sites regularly to avoid lipohypertrophy.

Interpreting Calcium, Phosphate, and Parathyroid Hormone Levels in a Patient with Prolonged Hypercortisolism

A patient presents with diffuse bone pain and laboratory results show decreased calcium and phosphate levels, along with increased parathyroid hormone levels. This is indicative of secondary hyperparathyroidism, which is a common complication of hypercortisolism. Elevated serum cortisol levels can lead to hypocalcaemia and secondary hyperparathyroidism, causing increased osteoclast activity and osteoblast dysfunction, ultimately resulting in osteoporosis and pathological fractures.

If the patient had increased phosphate levels instead of decreased levels, it would suggest renal impairment. If the patient had increased calcium levels and decreased phosphate levels, it would suggest primary hyperparathyroidism. If the patient had decreased calcium levels and increased phosphate levels, it would suggest hypoparathyroidism. If all levels were normal, it may be too early in the course of hypercortisolism to see changes in these markers.

In summary, interpreting calcium, phosphate, and parathyroid hormone levels can provide valuable information in diagnosing and managing complications of hypercortisolism.